Interestingly, some of the immunomodulating agents currently used for MS, namely interferon beta, glatiramer acetate (GA) and—still under clinical trials—alemtuzumab, have been shown to increase serum and/or immune-cell levels of BDNF in MS patients, which was suggested as one of the possible modes of actions for these therapies [46,47,68]. This evidence concerns the gene BDNF and myeloid sarcoma.